tiprankstipranks
Trending News
More News >
Aligos Therapeutics (ALGS)
NASDAQ:ALGS

Aligos Therapeutics (ALGS) AI Stock Analysis

Compare
217 Followers

Top Page

AL

Aligos Therapeutics

(NASDAQ:ALGS)

Rating:53Neutral
Price Target:
$7.00
▼(-5.28%Downside)
Aligos Therapeutics presents a high-risk, high-reward scenario typical of early-stage biotech firms. Financial performance is the most significant concern, with ongoing losses and negative cash flows. Technical indicators provide some short-term optimism, but longer-term trends are weak. The valuation score is low due to negative earnings, making it a speculative investment.
Positive Factors
Antiviral Activity
ALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.
Phase 2 Study Milestone
The initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.
Regulatory Support
Aligos is moving toward a more attainable goal, and one that is expected to be supported and endorsed by the FDA, EMA, and NMPA.
Negative Factors
Competition with Standard Treatment
ALG-000184 achieved the primary endpoint in 100% of patients in the Phase 1 study, compared to 21% for the standard-of-care treatment.
Safety Profile
ALG-000184 showed a favorable safety profile, with no viral breakthroughs or known CAM-resistant mutations reported with ALG-000184 monotherapy treatment.

Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)

Aligos Therapeutics Business Overview & Revenue Model

Company DescriptionAligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.
How the Company Makes MoneyAligos Therapeutics generates revenue primarily through research and development partnerships, licensing agreements, and collaboration with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of successfully commercialized products. Aligos also seeks funding from government grants and other sources to support its clinical trials and research initiatives. The company’s financial performance is closely tied to the progress and outcomes of its clinical trials, regulatory approvals, and the commercial success of its developed therapies.

Aligos Therapeutics Financial Statement Overview

Summary
Aligos Therapeutics struggles with profitability, showing ongoing losses and negative cash flows typical for early-stage biotech firms. Despite a robust balance sheet with low leverage, the persistent cash burn and negative profitability metrics are significant risks.
Income Statement
45
Neutral
Aligos Therapeutics shows a volatile revenue pattern with a decline to $3.27M in TTM from $15.53M in 2023. Despite improving gross profit margins, ongoing losses with a net profit margin of -1628% in TTM highlight persistent challenges in achieving profitability. The EBIT and EBITDA margins also remain negative, indicating operational inefficiencies.
Balance Sheet
55
Neutral
The balance sheet indicates a relatively stable equity position with stockholders' equity at $116.45M, although the negative net income affects ROE. The debt-to-equity ratio of 0.07 suggests low leverage, which is favorable, but the negative equity in previous years is a concern. The equity ratio stands at 77%, reflecting a strong asset base.
Cash Flow
50
Neutral
Cash flow analysis reveals negative operating cash flow of -$78.91M, with free cash flow remaining negative at -$79.01M. However, strong financing cash flow at $102.12M in TTM supports liquidity. The operating cash flow to net income ratio shows inefficiency in converting net income to cash, a risk for future operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.27M3.94M15.53M13.91M4.36M0.00
Gross Profit1.99M1.32M12.46M10.23M-99.79M-3.33M
EBITDA-84.50M-89.15M-85.06M-93.91M-124.54M-105.06M
Net Income-53.26M-131.21M-87.68M-96.05M-128.33M-108.54M
Balance Sheet
Total Assets150.70M70.09M151.53M146.69M235.37M265.30M
Cash, Cash Equivalents and Short-Term Investments137.86M56.94M135.70M125.83M190.73M243.51M
Total Debt7.87M8.38M11.14M12.57M14.46M13.01M
Total Liabilities34.25M99.07M59.45M42.79M50.64M45.26M
Stockholders Equity116.44M-28.97M92.08M103.90M184.73M220.04M
Cash Flow
Free Cash Flow-79.01M-80.87M-79.02M-80.33M-116.55M-76.33M
Operating Cash Flow-78.91M-80.74M-79.00M-79.39M-115.66M-74.26M
Investing Cash Flow26.30M-18.28M44.98M-26.29M3.02M32.76M
Financing Cash Flow102.12M355.00K88.33M164.00K78.68M192.35M

Aligos Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.39
Price Trends
50DMA
6.25
Positive
100DMA
9.42
Negative
200DMA
15.32
Negative
Market Momentum
MACD
0.28
Positive
RSI
52.33
Neutral
STOCH
25.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Negative. The current price of 7.39 is below the 20-day moving average (MA) of 7.42, above the 50-day MA of 6.25, and below the 200-day MA of 15.32, indicating a neutral trend. The MACD of 0.28 indicates Positive momentum. The RSI at 52.33 is Neutral, neither overbought nor oversold. The STOCH value of 25.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALGS.

Aligos Therapeutics Risk Analysis

Aligos Therapeutics disclosed 91 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aligos Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$15.27B5.80-7.43%4.22%11.60%-21.06%
57
Neutral
$207.34M-414.88%-65.96%40.80%
53
Neutral
$45.19M-60.44%-76.29%
42
Neutral
$21.45M-70.06%146.47%57.85%
41
Neutral
$35.97M-853.05%34.97%
35
Underperform
$39.95M-280.78%68.75%
30
Underperform
$45.58M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALGS
Aligos Therapeutics
7.31
-3.25
-30.78%
TVRD
Tvardi Therapeutics
21.45
11.66
119.10%
ANVS
Annovis Bio
2.38
-5.70
-70.54%
GBIO
Generation Bio
0.34
-2.10
-86.07%
PYPD
PolyPid
3.49
-0.51
-12.75%
NRSN
Neurosense Therapeutics Ltd.
1.90
0.58
43.94%

Aligos Therapeutics Corporate Events

Shareholder Meetings
Aligos Therapeutics Approves Major Amendments at Annual Meeting
Neutral
Jun 26, 2025

On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders where significant amendments to the company’s Certificate of Incorporation were approved. These amendments included increasing the number of authorized shares of voting common stock from 20 million to 100 million and non-voting common stock from 800,000 to 15.8 million. These changes, effective immediately upon filing with the Secretary of State of Delaware, are expected to impact the company’s capital structure significantly. Additionally, stockholders voted on five proposals, including electing three Class II directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALGS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 27, 2025